The San Diego Biotech Survival Index: Local Firms Make Strong Rebound In First Half of 2009

9/23/09Follow @xconomy

(Page 4 of 4)

Optimer Pharmaceuticals (NASDAQ: OPTR)
Cash on hand: $51.2 million
Previous Xconomy coverage:
Optimer Rides Investment See-Saw With Promising Drug for C.Diff Infections
Optimer Sharpens Up Commercial Game Plan After C.Diff Drug Success
Optimer’s Second Drug for Traveler’s Diarrhea Follows Fast Behind Lead C.Diff Antibiotic
Optimer Shares Skyrocket As Drug Halts Deadly Bacterial Infection in Trial

Orexigen Therapeutics (NASDAQ: OREX)
Cash on hand: $46 million
Previous Xconomy coverage:
Orexigen Aims to Redefine Obesity as Amgen Vet Revamps Company to Compete
Orexigen Drug Hits Weight Loss Goal in Studies, Company Looks Toward FDA
Orexigen Obesity Drug Produces Modest Weight Loss, Lowers Cardiovascular Risk

Quidel (NASDAQ: QDEL)
Cash on hand: $49.4 million
Previous Xconomy coverage:
Quidel, Pulling Off a Turnaround, Predicts Record Profit on Demand for Flu Tests

Santarus (NASDAQ: SNTS)
Cash on hand: $57.5 million
Previous Xconomy coverage:
Santarus Takes on Marketing Goliaths With Faster Acting Heartburn Drug
Santarus Nabs U.S. Rights for Two Drugs in Cosmo Collaboration

Sequenom (NASDAQ: SQNM)
Cash on Hand: $69.3 million
Previous Xconomy coverage:
Sequenom Maintains Tight Lid on Mishandled Data of Key Diagnostic Test
Sequenom, Fueled by Blood Test for Down’s, Aims To Be the Google of Molecular Diagnostics
Sequenom Blood Test Clears Higher Hurdle, Company Plots Aggressive Moves Toward Market

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button.
For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. Add to Cart
*Price is subject to change without notice.

Somaxon Pharmaceuticals (NASDAQ: SOMX)
Cash on hand: $1.3 million
Previous Xconomy coverage:
Somaxon Renews Its Insomnia Drug Application, Raises $6m
FDA Rejects Somaxon’s Application for Insomnia Drug

Torrey Pines Therapeutics (NASDAQ: TPTX)
Cash on hand: $1.2 million
Previous Xconomy coverage:
Wanted at Torrey Pines Therapeutics: Shareholders Who Vote

Vical (NASDAQ: VICL)
Cash on hand: $49 million
Previous Xconomy coverage:
Vical on Fast Pace With Animal Tests of Prototype Swine Flu Vaccine
After Years of Red Ink, Vical Says DNA-Based Vaccines Ready for Prime Time

Single Page Currently on Page: 1 2 3 4 previous page

By posting a comment, you agree to our terms and conditions.